Beam Therapeutics Inc
BEAMHealthcare|Biotechnology|USA
$24.07
-0.17 (-0.68%)
Tangible Book
$12.17
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06735755 A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) | Glycogen Storage Disease Type Ia | P1P2 | Recruiting | 36 | Open-label | BEAM-301: Single dose of BEAM-301 administered by IV |
| NCT05885464 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma | P1P2 | Active | 5 | Open-label | BEAM-201 |
| NCT06389877 A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) | Alpha 1-Antitrypsin Deficiency | P1P2 | Recruiting | 106 | Open-label | BEAM-302 |
| NCT05456880 BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease | Sickle Cell Disease | P1P2 | Active | 15 | Open-label | BEAM-101 |
| NCT06934382 Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | P1 | Recruiting | 33 | Open-label | Allogeneic anti-CD7 CAR-T cells (BEAM-201) |
| NCT07304791 This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects | Healthy Subjects, Healthy Participant Study | P1 | Recruiting | 30 | RCT, Single-blind | BEAM-103, Placebo Comparator |
| NCT06071377 Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT) | Sickle Cell Trait | Recruiting | 1,000 | — | — | |
| NCT07373639 A Long-term Follow-up Study in Patients Who Received BEAM-101 | Hemoglobinopathy, Sickle Cell Disease | Recruiting | 50 | — | Long-Term Follow-up Study of patients who received BEAM-101 | |
| NCT07137195 Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) | Solid Tumor, Adult | N/A | Active | 47 | Open-label | — |
| NCT07152353 Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) | Solid Tumor, Adult | N/A | Active | 47 | Open-label | — |
| NCT06397560 PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial | Glioma, Glioma, Malignant | N/A | Recruiting | 28 | Open-label | — |
| NCT07153094 Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen) | Solid Tumor, Adult | N/A | Active | 47 | Open-label | — |
| NCT07183735 A Crossover Trial to Examine the Efficacy of a Powder to Improve Sleep Quality and Performance | Sleep, Sleep Disorder | N/A | Completed | 40 | RCT, Double-blind | — |
| NCT05521243 An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quantity | Sleep, Sleep Disturbance | N/A | Completed | 64 | RCT, Double-blind | — |